http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105439914-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C235-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4409 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C303-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4402 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C231-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-166 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18 |
| filingDate | 2014-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105439914-B |
| titleOfInvention | 4 aminoacyl phenoxy acetamide class compounds and its medicinal usage |
| abstract | The invention belongs to medicinal chemistry art, it is related to 4 aminoacyl phenoxy acetamide class compounds and its medicinal usage shown in Formulas I structure, wherein described G, Z, R, m and n are consistent with the detailed description in the content of the invention.Such compound can suppress sphingomyelins synthase activity, can be used to treat the disease caused by sphingomyelin levels increase extremely.The present invention further includes compound as shown in Formulas I structure, its pharmaceutically acceptable salt or the pharmaceutical composition with it as effective active composition in prevention and treatment due to the application in the disease caused by sphingomyelin levels increase extremely.The disease caused by sphingomyelin levels increase extremely includes atherosclerosis, fatty liver, obesity and metabolic syndrome etc. type II diabetes. |
| priorityDate | 2014-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 178.